Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
January 21, 2022

Senhwa Biosciences receives ODD for Silmitasertib from FDA to treat biliary tract cancer

Senhwa Biosciences has announced the receipt of Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for Silmitasertib, a highly selective inhibitor of casein kinase 2 (CK2) to treat patients with biliary tract cancer (BTC).

Continue
ODD status is given to those drugs and biologics meant for treatment, prevention or diagnosis of a life-threatening or chronically debilitating rare disease. Credit: Michal Jarmoluk from Pixabay
January 10, 2022

Absci and Merck collaborate to develop new enzymes

Merck has the option to pick up to three targets and move into a drug discovery collaboration agreement. Credit: National Cancer Institute on Unsplash.
January 10, 2022

AbbVie seeks approval for upadacitinib to treat nr-axSpA

AbbVie seeks FDA and EMA approval for upadacitinib to treat non-radiographic axial spondyloarthritis. Credit: Hal Gatewood on Unsplash.

Contracts

January 12, 2022

Neogene Therapeutics signs global license agreement with NCI for cancer treatment

Neogene plans to evaluate both autologous and allogeneic T cell therapies targeting neoantigens in a broad spectrum of solid cancer. Credit: Arek Socha from Pixabay

Ovid signs license deal with AstraZeneca to expand epilepsy drug pipeline

Merck, Ridgeback to supply 1.75 million molnupiravir courses to UK

Recursion, Roche, Genentech collaborate in neuroscience, oncology

Deals

Deals January 18, 2022

Neurimmune and Ono Pharmaceutical extend drug discovery partnership 

Pharmaceutical Business Review

Prellis, Bristol Myers Squibb collaborate to discover antibodies

Pfizer, Beam sign multi-target research collaboration for rare diseases

Pfizer and Biohaven close collaboration agreements

Popular

  1. Galapagos’ Jyseleca gets UK marketing authorization for ulcerative colitis 
  2. US FDA approves Pfizer’s Cibinqo for atopic dermatitis treatment
  3. Lantern Pharma and NCI expand oncology partnership
  4. Amgen, Generate Biomedicines partner to create protein therapeutics
  5. FDA grants breakthrough designation to AbbVie’s Teliso-V for NSCLC treatment

PRESS RELEASES

2022 Pharmaceutical Training Courses from NSF
2022 Pharmaceutical Training Courses from NSF
60 Years of NETZSCH-Gerätebau
60 Years of NETZSCH-Gerätebau
Procaps Group Acquires First US-Based Softgel Production Facility and Pharmaceutical R&D Center to Expand Global Growth of its iCDMO Business Unit
Procaps Group Acquires First US-Based Softgel Production Facility and Pharmaceutical R&D Center to Expand Global Growth of its iCDMO Business Unit
UGA Biopharma Partners with Tosoh Bioscience on Cell Line and USP Technology Transfer to Generate New DSP Knowledge
UGA Biopharma Partners with Tosoh Bioscience on Cell Line and USP Technology Transfer to Generate New DSP Knowledge
Gerresheimer Enters Agreement with Major American Biotech to Develop an Innovative Pump for Rare Diseases
Gerresheimer Enters Agreement with Major American Biotech to Develop an Innovative Pump for Rare Diseases

Suppliers

Whitepapers

Deeper Insight into the Pyrolysis of Acetylsalicylic Acid by Means of Kinetic Analysis
Deeper Insight into the Pyrolysis of Acetylsalicylic Acid by Means of Kinetic Analysis
Affinity Tag Coating Enables Reliable Detection of Antigen-Specific B Cells in Immunospot Assays
Affinity Tag Coating Enables Reliable Detection of Antigen-Specific B Cells in Immunospot Assays
Deuterium-Containing Building Blocks for Drug Design
Deuterium-Containing Building Blocks for Drug Design